What is Heart Failure with Preserved Ejection Fraction (HFpEF) and Who Does It Impact?Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a complex disease characterized by amyloid fibril deposition in the heart. Current and emerging advances in disease-modifying therapies for this disease that will change clinical practice are evolving rapidly. Interact with HFSA faculty as they review and answer questions about the recently presented clinical trial data and how these findings may impact patient care. This program was supported by an Independent Medical Education Grant from BridgeBio Pharma, Inc. Watch now!CardioAbstracts: Heart Failure & Kidney Link. HFSA’s Cardio Abstracts program delivers expert-led discussions on recently presented clinical trial data in a convenient, interactive format. This 45-minute live seminar features Q&A with leading clinicians, recordings, and downloadable resources available for on-demand learning. This program is designed to support diverse learning styles and provide practical insights for clinicians specializing in heart failure care.
Chronic kidney disease (CKD) impacts nearly 50% of individuals with heart failure, characterized by mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF). Patients with these conditions also often have other disorders, such as atrial fibrillation or type 2 diabetes mellitus, which can result in worse health outcomes than any of these conditions would produce individually. Join HFSA faculty as they review and answer questions about the recently presented clinical trial data and how HF and CKD may impact patient care. Support for this program is provided by a grant from Bayer. Watch now!